About 10 results found for searched term "H-2-Nal-OH" (0.127 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M39491 | H-D-2-Nal-OH | Amino Acid Derivatives |
| H-D-2-Nal-OH is an alanine derivative. | ||
| M39517 | H-2-Nal-OH | Amino Acid Derivatives |
| H-2-Nal-OH is an alanine derivative. | ||
| M14764 | RTI-13951-33 hydrochloride | Others |
| RTI-13951-33 hydrochloride is a potent, selective, and brain-penetrant GPR88 agonist, with an EC50 of 25 nM in GPR88 cAMP functional assay. RTI-13951-33 hydrochloride reduces alcohol reinforcement and intake behaviors in rats. | ||
| M24907 | Pegbelfermin | FGFR |
| BMS-986036 | ||
| Pegbelfermin (BMS-986036) is a polyethylene glycol-modified (PEGylated) analogue of human fibroblast growth factor 21 (FGF21). Pegbelfermin can be used for the research of nonalcoholic steatohepatitis (NASH). | ||
| M29415 | RTI-13951-33 | GPR/FFAR |
| RTI-13951-33 is a potent, selective, and brain-penetrant GPR88 agonist, with an EC50 of 25 nM in GPR88 cAMP functional assay. RTI-13951-33 reduces alcohol reinforcement and intake behaviors in rats. | ||
| M29847 | BI‑3231 | Hydroxysteroid dehydrogenase |
| BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases. | ||
| M40611 | PF-04236921 | IL Receptor/Related |
| PF-04236921 is a fully human IgG2 monoclonal antibody targeting the interleukin IL-6 for studies related to Crohn's disease and rheumatoid arthritis. | ||
| M40875 | Brazikumab | IL Receptor/Related |
| AMG 139; MEDI2070 | ||
| Brazikumab is a human IgG2 monoclonal antibody targeting IL-23 that selectively binds to the p19 subunit of IL-23 and has a KD value of 0.138 nM against human IL-23 for Crohn's disease (CD). | ||
| M42893 | Cisd2 agonist 2 | Others |
| Cisd2 agonist 2 is an orally active Cisd2 activator (EC50=191 nM), while the Cisd2 levels is correlated with nonalcoholic fatty liver disease (NAFLD). | ||
| M49467 | Carfloglitazar sodium | PPAR |
| Chiglitazar sodium | ||
| Carfloglitazar sodium is a dual agonist of the pan peroxisome proliferator-activated receptor (PPARα/γ) with EC50 values of 1.2, 0.08, and 1.7 μM for PPARα, PPARγ, and PPARδ, respectively.It can be used in studies related to nonalcoholic steatohepatitis (NASH). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
